868071-17-4

Basic information

• Product Name: (3S)-2',4',5'-Trifluoro-3-hydroxybenzenebutanoic acid
• Synonyms: (S)-3-HYDROXY-4-(2,4,5-TRIFLUORO-PHENYL)-BUTYRIC ACID;(3S)-2',4',5'-Trifluoro-3-hydroxybenzenebutanoic acid;(S)-3-Hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid
• CAS NO: 868071-17-4
• Molecular Formula: C₁₀H₉F₃O₃
• Molecular Weight: 234.1718696
• Mol File: 868071-17-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 87 ºC
• Boiling Point: 340.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.459
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.24±0.10(Predicted)
• CAS DataBase Reference: (3S)-2',4',5'-Trifluoro-3-hydroxybenzenebutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-2',4',5'-Trifluoro-3-hydroxybenzenebutanoic acid(868071-17-4)
• EPA Substance Registry System: (3S)-2',4',5'-Trifluoro-3-hydroxybenzenebutanoic acid(868071-17-4)

Safety Data

• Hazardous Substances Data: 868071-17-4(Hazardous Substances Data)

Usage

Uses

Dexrazoxane intermediate

Upstream product

• 165047-24-5 2,4,5-trifluorobenzaldehyde 
• 17533-08-3 1-iodo-2,4,5-trifluorobenzene 
• 1365321-55-6 (2S)-3-(2,4,5-trifluorophenyl)propane-1,2-diol 
• 868071-16-3 3(S)-4-(2,4,5-trifluorophenyl)-3-hydroxybenzenebutanoic acid methyl ester 
• 764667-64-3 5-(1-hydroxy-2-(2,4,5-trifluorophenyl)ethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 769195-26-8 4-(2,4,5-trifluoro-phenyl)-3-oxo-butyric acid methyl ester 
• 209995-38-0 (2,4,5-trifluorophenyl)acetic acid 
• 7647-01-0 hydrogenchloride 
• 1138326-05-2 (R)-methyl 3-hydroxy-4-(2,4,5-trifluorophenyl)butanoate 
• 1352613-29-6 (S)-ethyl 3-hydroxy-4-(2,4,5-trifluorophenyl)butanoate 
• 1283096-73-0 2-(2,4,5-trifluorobenzyl)-oxirane 
• 1246960-15-5 (S)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol 
• 680993-47-9 1-allyl-2,4,5-trifluorobenzene 
• 327-52-6 1-bromo-2,4,5-trifluorobenzene 

Downstream Products

• 1256815-04-9 N-benzyloxy-4-(2,4,5-trifluorophenyl)-3(S)-hydroxybutanamide 
• 1352613-36-5 (S)-3-hydroxy-N-methoxy-4-(2,4,5-trifluorophenyl)butanamide 
• 1352613-30-9 (S)-3-hydroxy-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one 
• 486460-32-6 sitagliptin 
• 1253055-98-9 (R)-3-azido-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one 
• 654671-78-0 (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate 
• 1352613-37-6 (S)-4-(methoxyamino)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-yl methane-sulfonate 
• 1352613-38-7 (S)-4-(benzyloxyamino)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-yl methanesulfonate 
• 1352613-39-8 (R)-1-methoxy-4-(2,4,5-trifluorobenzyl)azetidin-2-one 
• 1352613-40-1 (R)-3-(methoxyamino)-4-(2,4,5-trifluorophenyl)butanoic acid 
• 1352613-41-2 (R)-3-(methoxyamino)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one 
• 1352613-31-0 (S)-3-(methanesulfonyloxy)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one 
• 767352-30-7 N-(benzyloxy)-4(R)-[1-methyl-(2,4,5-trifluorophenyl)]-2-oxoazetidine 
• 1352613-29-6 (S)-ethyl 3-hydroxy-4-(2,4,5-trifluorophenyl)butanoate 

Relevant articles and documents

A novel synthesis of (2S)-3-(2,4,5-trifluorophenyl)propane-1,2-diol by sharpless asymmetric epoxidation method

Synthesis of (2S)-3-(2,4,5-trifluorophenyl)propane-1,2-diol by the Sharpless asymmetric epoxidation reaction has been achieved. 2,4,5-Trifluorobenzaldehyde with methyl 2-(triphenyl-λ5-phosphanylidene)acetate gave methyl (E)-3-(2,4,5-trifluorophenyl)acrylate in 83% yield. The reduction of ester group with DibalH followed by Sharpless asymmetric epoxidation gave ((2R,3R)-3-(2,4,5-trifluorophenyl)oxiran-2-yl)methanol. Pd/C-catalyzed hydrogenation of epoxy alcohol furnished (2S)-3-(2,4,5-trifluorophenyl)propane-1,2-diol with >90% ee and 71% yield.

SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF

The present invention relates to an improved process for preparation of Sitagliptin or pharmaceutically acceptable salts thereof. The present invention further relates to novel polymorphs of Sitagliptin salts and process for preparation thereof.

PROCESSES FOR THE PREPARATION OF R-SITAGLIPTIN AND INTERMEDIATES THEREOF

The present invention relates to the synthesis of R-sitagliptin. The present invention also relates to a compound of formula (IV) or its salt, that are useful as key intermediate in the synthesis of R-sitagliptin or pharmaceutically acceptable salts thereof.